All In Biotech

Drug Trial Radar · NCT07424690

Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation

Assessment of the Effect of Catheter Ablation on Elderly Population With Atrial Fibrillation; a Randomized Controlled Study; The ACE-AF Study

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 282 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

282

Planned (sponsor's estimate)

Start

Oct 5, 2026

Primary completion

Dec 15, 2031

Study completion Sep 15, 2034

Sponsor

Lead sponsor
Karolinska University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University Hospital, Linkoeping; Sahlgrenska University Hospital; University Hospital, Umeå; Dept of Cardiology, Örebro University Hospital, Sweden; Lund University Hospital; Onassis Cardiac Surgery Centre; Uppsala University Hospital; Royal Adelaide Hospital
First posted
Feb 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 78 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ACE-AF is a multicenter randomized study in people aged 78 years and older with symptomatic atrial fibrillation (AF). AF is a common heart rhythm disorder in older adults and can cause reduced quality of life and lead to serious complications such as stroke and heart failure. The study compares two established treatment strategies: 1. Catheter ablation (an invasive procedure aimed at reducing AF by electrically isolating triggers in the heart, primarily through pulmonary vein isolation), and 2. Optimized medical therapy without AF ablation (medications for rate and/or rhythm control; AV node ablation with pacemaker may be used if clinically indicated according to routine care). Participants are randomized 1:1 to one of these strategies. All participants will receive an implantable loop recorder (a small heart rhythm monitor placed under the skin) to continuously track heart rhythm and measure AF burden over time. The study has two primary endpoints, tested with Holm-Bonferroni multiplicity control assessed over 24 months: 1. a composite of major clinical events (all-cause mortality, stroke, major bleeding, cardiac arrest, or hospitalization due to heart failure), and 2. patient-reported health-related quality of life (HRQoL), measured by the RAND-36 "General Health" domain. ACE-AF will provide evidence to guide treatment decisions for very elderly patients with symptomatic AF and help identify which patients benefit most from an ablation-based strategy compared with optimized medical therapy.

Conditions

  • Atrial Fibrillation (AF)
  • Atrial Fibrillation Ablation
  • Elderly

Interventions

  • Catheter Ablation for Atrial FibrillationProcedure

    Catheter ablation for symptomatic atrial fibrillation with pulmonary vein isolation (PVI) prioritized as the primary lesion set. Energy source and tools are selected according to local practice and operator discretion (no restriction to a specific technology), performed under routine standards of care at experienced centres.

  • Optimized Medical Therapy for Atrial FibrillationDrug

    Guideline-directed rate and/or rhythm control tailored to the participant's clinical condition, including rate-control medications and/or antiarrhythmic drugs and cardioversion when clinically appropriate. AF ablation is not performed as part of this strategy.

  • Implantable Loop Recorder (ILR)Device

    Subcutaneous implantable loop recorder used for continuous rhythm monitoring and quantification of atrial fibrillation burden throughout follow-up. Implanted in all participants according to protocol-defined workflow.

  • AV Node Ablation With Pacemaker implantationProcedure

    AV node ablation with permanent pacing may be performed when clinically indicated according to routine care, as part of the optimized medical therapy strategy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite clinical endpoint (all-cause mortality, stroke, serious bleeding, cardiac arrest, or heart failure hospitalization)Time frame: 24 months after intervention (visit 2)
  2. Change in RAND-36 General Health scoreTime frame: Baseline to 24 months after intervention (visit 2)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Linköping University Hospital

    Linköping, Sweden · Not yet recruiting

  • Karolinska University Hospital

    Stockholm, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.